Document Type
Conference Proceeding - Restricted Access
Publication Date
3-8-2022
Publication Title
Journal of the American College of Cardiology
Abstract
Background: Amiodarone is a commonly used anti-arrhythmic drug in the elderly. The effect of amiodarone therapy in patients with pre-existing cardiac implantable electronic devices (CIEDs) undergoing transcatheter aortic valve replacement (TAVR) is not previously reported Methods: We retrospectively reviewed patients with pre-existing CIEDs undergoing TAVR at a large tertiary care hospital. Patients were grouped based on amiodarone exposure perioperatively (Am) vs no exposure (NoAm). Multivariate Cox-proportional Hazard ratio and Kaplan Meier curves were generated to evaluate mortality in these two groups Results: Of the 865 patients who underwent TAVR from 2012 to 2020, 113 patients (13.1%) had pre-existing CIEDs prior to TAVR. Am consisted of 15 (13.3%) patients (mean age 82.4 ± 10.5, 53.3% males) while NoAm included 98 (86.7%) patients (mean age 83.1 ± 9.4, 56% males). Atrial fibrillation was present in 86.7% of Am vs 65.3% of NoAm (P= 0.1751). Amiodarone use was associated with increased mortality after adjusting for baseline characteristics and presence of atrial fibrillation (HR 2.38, CI 1.19-4.75, P= 0.0138), with a median survival of 29 months in Am group versus 60 months in NoAm (P=0.005). Conclusion: Amiodarone use was independently associated with increased mortality in patients with CIEDs undergoing TAVR.
Volume
79
Issue
9 Suppl
First Page
208
Last Page
208
Recommended Citation
Madanat L, Seeley E, Shah K, Haines DE, Mehta N. Effect of amiodarone use in patients with pre-existing cardiac implantable electronic devices undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2022 Mar 8;79(9 Suppl):208.